Clinical outcomes after idecabtagene vicleucel in older patients with multiple myeloma: a multicenter real-world experience.

Blood Adv · 2024 · PMC11402173 · PMID 39042903

Europe PMC DOI

hedged sentence

0.1000

closest p · 2.0× alpha

0.1000

boldest claim

The sentences

reached borderline significanceP < .1so close (0.05 < p ≤ 0.1)

The median time to maximum grade ICANS was shorter at 1.5 days for older patients compared with 3 days in younger patients and the difference reached borderline significance ( P < .1).

also in 93 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.